David Leiman, MD
Gastroenterology · Durham, NCNPI 1558596403
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Covidien LP at 46.3% of the total. Reporting peaked in 2020 at $6,310 and has fallen 95.2% since, to $305 in 2025.
Across 23 payments — averaging $604.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$6K
- Merck$3K
- Regeneron$3K
- Sanofi$1K
- Pfizer$600
- Ferring Pharmaceuticals Inc.$60
Across 180 payments — averaging $8210.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$902K
- Regeneron$231K
- Ironwood Pharmaceuticals, Inc$186K
- Pfizer$91K
- Phathom Pharmaceuticals, Inc.$25K
- E.r. Squibb & Sons, L.L.C.$19K
- plus $24K from 2 others
What the payments were for
- Consulting fees$7,15251%
- Speaking & faculty fees$6,31045%
- Food & beverage$3663%
- Education$771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 6 | $6,442 |
| Merck | 7 | $2,807 |
| Regeneron | 1 | $2,548 |
| Sanofi | 7 | $1,449 |
| Pfizer | 1 | $600 |
| Ferring Pharmaceuticals Inc. | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,906 in reported general payments places this provider in the 85th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 22 | $8,801 |
| LinzessLinaclotide | 12 | $7,467 |
| Omeprazole | 138 | $2,192 |
| Esomeprazole Magnesium | 28 | $1,363 |
| Pantoprazole Sodium | 52 | $774 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 28 | $595 |
| Famotidine | 29 | $429 |
| Oxycodone Hcl | 12 | $175 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Durham
- Manal AbdelmalekDurham$402K
- Andrew MuirDurham$56K
- Elizabeth GoacherDurham$41K
- Keyur PatelDurham$41K
- Anna Mae DiehlDurham$36K
- Jeremy Glissen BrownDurham$27K
- Nancy McGrealDurham$26K
- Stephen DealCharlotte$945K
- Fred FowlerCharlotte$932K
- Paul WatkinsChapel Hill$876K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.